Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
J Gastroenterol
    August 2022
  1. ZHOU Q, Wang X, Li R, Wang C, et al
    Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
    J Gastroenterol. 2022 Aug 3. pii: 10.1007/s00535-022-01910.
    >> Share

    July 2022
  2. KODAMA K, Kawaoka T, Kosaka M, Johira Y, et al
    Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
    J Gastroenterol. 2022 Jul 18. pii: 10.1007/s00535-022-01887.
    >> Share

  3. ZHOU Q, Wang X, Li R, Wang C, et al
    Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
    J Gastroenterol. 2022 Jul 11. pii: 10.1007/s00535-022-01895.
    >> Share

  4. LIU T, Liao S, Mo J, Bai X, et al
    LncRNA n339260 functions in hepatocellular carcinoma progression via regulation of miRNA30e-5p/TP53INP1 expression.
    J Gastroenterol. 2022 Jul 8. pii: 10.1007/s00535-022-01901.
    >> Share

  5. OKUSHIN K, Tateishi R, Takahashi A, Uchino K, et al
    Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL).
    J Gastroenterol. 2022 Jul 5. pii: 10.1007/s00535-022-01893.
    >> Share

    June 2022
  6. KARIYAMA K, Hiraoka A, Kumada T, Yasuda S, et al
    Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade).
    J Gastroenterol. 2022 Jun 28. pii: 10.1007/s00535-022-01883.
    >> Share

    May 2022
  7. AMPUERO J, Gallego-Duran R, Maya-Miles D, Montero R, et al
    Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.
    J Gastroenterol. 2022;57:357-371.
    >> Share

    April 2022
  8. NISHIDA N, Yamakawa M, Shiina T, Mekada Y, et al
    Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts.
    J Gastroenterol. 2022;57:309-321.
    >> Share

  9. IRITANI S, Kawamura Y, Muraishi N, Fujiyama S, et al
    The useful predictors of zinc deficiency for the management of chronic liver disease.
    J Gastroenterol. 2022;57:322-332.
    >> Share

    March 2022
  10. SUZUKI Y, Mori T, Momose H, Matsuki R, et al
    Predictive factors for subsequent intrahepatic cholangiocarcinoma associated with hepatolithiasis: Japanese National Cohort Study for 18 years.
    J Gastroenterol. 2022 Mar 31. pii: 10.1007/s00535-022-01868.
    >> Share

  11. LIN W, Lin J, Li J, Lin Y, et al
    Kindlin-2-miR-1258-TCF4 feedback loop promotes hepatocellular carcinoma invasion and metastasis.
    J Gastroenterol. 2022 Mar 4. pii: 10.1007/s00535-022-01866.
    >> Share

    February 2022
  12. WANG XH, Hu ZL, Fu YZ, Hou JY, et al
    Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
    J Gastroenterol. 2022 Feb 13. pii: 10.1007/s00535-022-01855.
    >> Share

    January 2022
  13. SAKAMORI R, Yamada R, Tahata Y, Kodama T, et al
    The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery.
    J Gastroenterol. 2022 Jan 22. pii: 10.1007/s00535-021-01842.
    >> Share

  14. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
    J Gastroenterol. 2022 Jan 20. pii: 10.1007/s00535-021-01845.
    >> Share

  15. SEKO Y, Moriguchi M, Takahashi A, Yamaguchi K, et al
    Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
    J Gastroenterol. 2022 Jan 15. pii: 10.1007/s00535-021-01837.
    >> Share

    December 2021
  16. BURGHART L, Halilbasic E, Schwabl P, Simbrunner B, et al
    Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis.
    J Gastroenterol. 2021 Dec 11. pii: 10.1007/s00535-021-01839.
    >> Share

  17. NAKAYAMA N, Uemura H, Uchida Y, Imai Y, et al
    Nationwide survey for patients with acute-on-chronic liver failure occurring between 2017 and 2019 and diagnosed according to proposed Japanese criteria.
    J Gastroenterol. 2021;56:1092-1106.
    >> Share

  18. KAMADA Y, Takahashi H, Shimizu M, Kawaguchi T, et al
    Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review.
    J Gastroenterol. 2021;56:1045-1061.
    >> Share

    November 2021
  19. MATSUMOTO K, Ohfuji S, Abe M, Komori A, et al
    Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.
    J Gastroenterol. 2021 Nov 18. pii: 10.1007/s00535-021-01836.
    >> Share

  20. YONEDA M, Yamamoto T, Honda Y, Imajo K, et al
    Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    J Gastroenterol. 2021;56:1022-1032.
    >> Share

    September 2021
  21. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01821.
    >> Share

  22. TOKUSHIGE K, Ikejima K, Ono M, Eguchi Y, et al
    Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01796.
    >> Share

    July 2021
  23. LI D, Ding X, Tian D, Xia L, et al
    Reply to: "COVID-19-associated liver injury (COVALI): role of hepatologists".
    J Gastroenterol. 2021 Jul 12. pii: 10.1007/s00535-021-01807.
    >> Share

  24. YOSHIJI H, Nagoshi S, Akahane T, Asaoka Y, et al
    Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
    J Gastroenterol. 2021 Jul 7. pii: 10.1007/s00535-021-01788.
    >> Share

  25. SUMIDA Y, Yoneda M
    COVID-19-associated liver injury (COVALI): role of hepatologists.
    J Gastroenterol. 2021 Jul 2. pii: 10.1007/s00535-021-01809.
    >> Share

    May 2021
  26. OKUSAKA T, Ikeda K, Kudo M, Finn R, et al
    Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    J Gastroenterol. 2021 May 4. pii: 10.1007/s00535-021-01785.
    >> Share

    March 2021
  27. MAK LY, Huang Q, Wong DK, Stamm L, et al
    Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy.
    J Gastroenterol. 2021 Mar 27. pii: 10.1007/s00535-021-01780.
    >> Share

  28. NAKATSUKA T, Nakagawa H, Hayata Y, Wake T, et al
    Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma.
    J Gastroenterol. 2021 Mar 12. pii: 10.1007/s00535-021-01773.
    >> Share

  29. HUO TI, Ho SY, Liu PH
    Changing patterns of etiology and management of hepatocellular carcinoma: need for global reappraisal.
    J Gastroenterol. 2021 Mar 11. pii: 10.1007/s00535-021-01770.
    >> Share

  30. ENOMOTO H, Nishiguchi S
    Reply to the letter by Huo et al. regarding our manuscript "The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan".
    J Gastroenterol. 2021 Mar 11. pii: 10.1007/s00535-021-01768.
    >> Share

  31. LI D, Ding X, Xie M, Tian D, et al
    COVID-19-associated liver injury: from bedside to bench.
    J Gastroenterol. 2021;56:218-230.
    >> Share

    February 2021
  32. ISHIKAWA T, Sasaki R, Nishimura T, Matsuda T, et al
    Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism.
    J Gastroenterol. 2021 Feb 24. pii: 10.1007/s00535-021-01762.
    >> Share

    January 2021
  33. TERAI S, Buchanan-Hughes A, Ng A, Lee IH, et al
    Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
    J Gastroenterol. 2021 Jan 26. pii: 10.1007/s00535-021-01759.
    >> Share

  34. TATEISHI R, Matsumura T, Okanoue T, Shima T, et al
    Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan.
    J Gastroenterol. 2021 Jan 11. pii: 10.1007/s00535-020-01754.
    >> Share

  35. KUDO M, Tsuchiya K, Kato N, Hagihara A, et al
    Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.
    J Gastroenterol. 2021 Jan 3. pii: 10.1007/s00535-020-01753.
    >> Share

  36. HARADA M
    Diagnosis for Wilson disease: this disease may not be a rare disease.
    J Gastroenterol. 2021;56:114-115.
    >> Share

  37. GARCIA-VILLARREAL L, Hernandez-Ortega A, Sanchez-Monteagudo A, Pena-Quintana L, et al
    Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity.
    J Gastroenterol. 2021;56:78-89.
    >> Share

  38. JIANG L, Starkel P, Fan JG, Fouts DE, et al
    The gut mycobiome: a novel player in chronic liver diseases.
    J Gastroenterol. 2021;56:1-11.
    >> Share

    December 2020
  39. OCHI H, Hiraoka A, Hirooka M, Koizumi Y, et al
    Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.
    J Gastroenterol. 2020 Dec 5. pii: 10.1007/s00535-020-01747.
    >> Share

    November 2020
  40. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.
    J Gastroenterol. 2020 Nov 20. pii: 10.1007/s00535-020-01748.
    >> Share

  41. SUZUKI K, Suda G, Yamamoto Y, Furuya K, et al
    Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
    J Gastroenterol. 2020 Nov 19. pii: 10.1007/s00535-020-01750.
    >> Share

    October 2020
  42. YU WL, Yu G, Dong H, Chen K, et al
    Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2020 Oct 21. pii: 10.1007/s00535-020-01729.
    >> Share

  43. MIKI D, Akita T, Kurisu A, Kawaoka T, et al
    PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
    J Gastroenterol. 2020 Oct 15. pii: 10.1007/s00535-020-01731.
    >> Share

  44. TAHATA Y, Hikita H, Mochida S, Kawada N, et al
    Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    J Gastroenterol. 2020 Oct 1. pii: 10.1007/s00535-020-01733.
    >> Share

    September 2020
  45. YIP TC, Lai JC, Wong GL
    Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
    J Gastroenterol. 2020 Sep 24. pii: 10.1007/s00535-020-01726.
    >> Share

  46. HIRAMINE Y, Uto H, Mawatari S, Kanmura S, et al
    Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
    J Gastroenterol. 2020 Sep 21. pii: 10.1007/s00535-020-01727.
    >> Share

    August 2020
  47. UCHIDA Y, Uemura H, Yamaba S, Hamada D, et al
    Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19.
    J Gastroenterol. 2020 Aug 9. pii: 10.1007/s00535-020-01717.
    >> Share

  48. ALI AH, Bi Y, Machicado JD, Garg S, et al
    The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience.
    J Gastroenterol. 2020 Aug 8. pii: 10.1007/s00535-020-01714.
    >> Share

  49. MARASCO G, Serenari M, Renzulli M, Alemanni LV, et al
    Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments.
    J Gastroenterol. 2020 Aug 3. pii: 10.1007/s00535-020-01711.
    >> Share

    July 2020
  50. TANAKA H, Okamoto K, Sato Y, Tanaka T, et al
    Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma.
    J Gastroenterol. 2020 Jul 14. pii: 10.1007/s00535-020-01705.
    >> Share

    June 2020
  51. LIANG LY, Wong VW, Toyoda H, Tse YK, et al
    Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.
    J Gastroenterol. 2020 Jun 17. pii: 10.1007/s00535-020-01700.
    >> Share

  52. SAWADA Y, Shiraki M, Iwasa M, Hiraoka A, et al
    The effects of diuretic use and the presence of ascites on muscle cramps in patients with cirrhosis: a nationwide study.
    J Gastroenterol. 2020 Jun 12. pii: 10.1007/s00535-020-01694.
    >> Share

    May 2020
  53. SAKAIDA I, Terai S, Kurosaki M, Okada M, et al
    Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    J Gastroenterol. 2020 May 9. pii: 10.1007/s00535-020-01691.
    >> Share

    March 2020
  54. KAWAGUCHI T, Torimura T
    Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients?
    J Gastroenterol. 2020;55:363-364.
    >> Share

    December 2019
  55. SCHWARZER R, Reiberger T, Mandorfer M, Kivaranovic D, et al
    The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.
    J Gastroenterol. 2019 Dec 12. pii: 10.1007/s00535-019-01656.
    >> Share

    May 2019
  56. NAGANUMA M, Sugimoto S, Suzuki H, Matsuno Y, et al
    Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey.
    J Gastroenterol. 2019 May 17. pii: 10.1007/s00535-019-01591.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016